Phillip Gambel

Array ( [id] => 11082274 [patent_doc_number] => 20160279239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'SUBCUTANEOUS ADMINISTRATION OF ANTI-CD74 ANTIBODY FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND AUTOIMMUNE DISEASE' [patent_app_type] => utility [patent_app_number] => 15/131655 [patent_app_country] => US [patent_app_date] => 2016-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 24509 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15131655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11025169 [patent_doc_number] => 20160222124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'ANTI-CD40 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/098388 [patent_app_country] => US [patent_app_date] => 2016-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 38782 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15098388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11018091 [patent_doc_number] => 20160215044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'HIGH CONCENTRATION FORMULATIONS OF ANTI-C5 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/096747 [patent_app_country] => US [patent_app_date] => 2016-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 42656 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15096747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12603432 [patent_doc_number] => 20180092974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/564904 [patent_app_country] => US [patent_app_date] => 2016-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15564904 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11011043 [patent_doc_number] => 20160207997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'ANTI-C5A ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/088421 [patent_app_country] => US [patent_app_date] => 2016-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 58963 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15088421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114951 [patent_doc_number] => 20160311924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'ANTI-KIT ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/084715 [patent_app_country] => US [patent_app_date] => 2016-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 88599 [patent_no_of_claims] => 60 [patent_no_of_ind_claims] => 43 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15084715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277237 [patent_doc_number] => 20190135903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => IDENTIFYING AND TREATING SUBPOPULATIONS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS [patent_app_type] => utility [patent_app_number] => 15/560606 [patent_app_country] => US [patent_app_date] => 2016-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14789 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11003856 [patent_doc_number] => 20160200805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'Complement Pathway Inhibitors Binding To C5 And C5a Without Preventing The Formation Of C5b' [patent_app_type] => utility [patent_app_number] => 15/076960 [patent_app_country] => US [patent_app_date] => 2016-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9410 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15076960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067718 [patent_doc_number] => 20160264682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'Inhibitors Of Complement Activation' [patent_app_type] => utility [patent_app_number] => 15/075364 [patent_app_country] => US [patent_app_date] => 2016-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 20585 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15075364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14171767 [patent_doc_number] => 10259879 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties [patent_app_type] => utility [patent_app_number] => 15/074505 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 13109 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15074505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851723 [patent_doc_number] => 20170226215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Antibody Therapeutics That Bind CD137' [patent_app_type] => utility [patent_app_number] => 15/050215 [patent_app_country] => US [patent_app_date] => 2016-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 35526 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15050215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11763021 [patent_doc_number] => 09371378 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-06-21 [patent_title] => 'Anti-C5a antibodies' [patent_app_type] => utility [patent_app_number] => 15/040258 [patent_app_country] => US [patent_app_date] => 2016-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 58980 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15040258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118822 [patent_doc_number] => 20180002408 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-01-04 [patent_title] => 'AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/013431 [patent_app_country] => US [patent_app_date] => 2016-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 11187 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15013431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118822 [patent_doc_number] => 20180002408 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-01-04 [patent_title] => 'AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/013431 [patent_app_country] => US [patent_app_date] => 2016-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 11187 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15013431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534553 [patent_doc_number] => 20190202898 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2019-07-04 [patent_title] => AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/012457 [patent_app_country] => US [patent_app_date] => 2016-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15012457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534553 [patent_doc_number] => 20190202898 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2019-07-04 [patent_title] => AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/012457 [patent_app_country] => US [patent_app_date] => 2016-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15012457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11083822 [patent_doc_number] => 20160280788 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'USE OF ANTIBODIES AGAINST ICAM-1 IN THE TREATMENT OF PATIENTS WITH RELAPSED CANCER' [patent_app_type] => utility [patent_app_number] => 15/007373 [patent_app_country] => US [patent_app_date] => 2016-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 28456 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15007373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12138244 [patent_doc_number] => 20180016327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'A Combination of Two or More Anti-C5 Antibodies and Methods of Use' [patent_app_type] => utility [patent_app_number] => 15/544930 [patent_app_country] => US [patent_app_date] => 2016-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 35869 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15544930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11408985 [patent_doc_number] => 09556278 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Anti-CD40 antibodies' [patent_app_type] => utility [patent_app_number] => 14/995741 [patent_app_country] => US [patent_app_date] => 2016-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 40 [patent_no_of_words] => 31404 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14995741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980010 [patent_doc_number] => 20160176954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'Anti-C5 Antibodies and Methods of Use' [patent_app_type] => utility [patent_app_number] => 14/974350 [patent_app_country] => US [patent_app_date] => 2015-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 51373 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14974350 [rel_patent_id] =>[rel_patent_doc_number] =>)